Patents by Inventor Meaghan Hancock

Meaghan Hancock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
    Patent number: 11305015
    Abstract: CMV vectors that lack active UL128, UL130, UL146 and UL147 proteins that may also comprise one or more microRNA regulatory elements (MRE) that restrict expression of the CMV are provided. Immunization with CMV vectors having the described features allows selection of different CD8+ T cell responses—CD8+ T cells restricted by MHC-Ia, MHC-II, or by MHC-E.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: April 19, 2022
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Louis Picker, Scott Hansen, Klaus Frueh, Daniel Malouli, Jay Nelson, Jonah Sacha, Meaghan Hancock
  • Cytomegalovirus Vectors Eliciting T Cells Restricted By Major Histocompatibility Complex E Molecules
    Publication number: 20200237915
    Abstract: Disclosed are CMV vectors that lack active UL128, UL130, UL146 and UL147 proteins that may also comprise one or more microRNA regulatory elements (MRE) that restrict expression of the CMV. Immunization with the disclosed CMV vectors allow selection of different CD8+ T cell responses—CD8+ T cells restricted by MHC-Ia, MHC-II, or by MHC-E.
    Type: Application
    Filed: November 26, 2019
    Publication date: July 30, 2020
    Inventors: Louis PICKER, Scott Hansen, Klaus Frueh, Daniel Malouli, Jay Nelson, Jonah Sacha, Meaghan Hancock
  • Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
    Patent number: 10532099
    Abstract: Disclosed are CMV vectors that lack active UL128, UL130, UL146 and UL147 proteins that may also comprise one or more microRNA regulatory elements (MRE) that restrict expression of the CMV. Immunization with the disclosed CMV vectors allow selection of different CD8+ T cell responses—CD8+ T cells restricted by MHC-Ia, MHC-II, or by MHC-E.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: January 14, 2020
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Louis Picker, Scott Hansen, Klaus Frueh, Daniel Malouli, Jay Nelson, Jonah Sacha, Meaghan Hancock
  • CYTOMEGALOVIRUS VECTORS ELICITING T CELLS RESTRICTED BY MAJOR HISTOCOMPATIBILITY COMPLEX E MOLECULES
    Publication number: 20180133321
    Abstract: Disclosed are CMV vectors that lack active UL128, UL130, UL146 and UL147 proteins that may also comprise one or more microRNA regulatory elements (MRE) that restrict expression of the CMV. Immunization with the disclosed CMV vectors allow selection of different CD8+ T cell responses—CD8+ T cells restricted by MHC-Ia, MHC-II, or by MHC-E.
    Type: Application
    Filed: October 18, 2017
    Publication date: May 17, 2018
    Inventors: Louis Picker, Scott Hansen, Klaus Frueh, Daniel Malouli, Jay Nelson, Jonah Sacha, Meaghan Hancock